Compare SBUX & SYK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBUX | SYK |
|---|---|---|
| Founded | 1971 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.0B | 120.4B |
| IPO Year | 1994 | 1994 |
| Metric | SBUX | SYK |
|---|---|---|
| Price | $100.98 | $310.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 14 |
| Target Price | $104.39 | ★ $415.57 |
| AVG Volume (30 Days) | ★ 7.6M | 2.4M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.35% | 1.12% |
| EPS Growth | N/A | ★ 8.25 |
| EPS | 0.70 | ★ 1.93 |
| Revenue | ★ $37,184,400,000.00 | $25,116,000,000.00 |
| Revenue This Year | $4.88 | $9.80 |
| Revenue Next Year | $5.15 | $8.44 |
| P/E Ratio | ★ $144.17 | $160.94 |
| Revenue Growth | 2.79 | ★ 11.16 |
| 52 Week Low | $77.99 | $281.00 |
| 52 Week High | $108.88 | $404.87 |
| Indicator | SBUX | SYK |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 49.81 |
| Support Level | $93.59 | $290.96 |
| Resistance Level | $101.18 | $319.17 |
| Average True Range (ATR) | 2.67 | 7.85 |
| MACD | 0.37 | 0.80 |
| Stochastic Oscillator | 69.75 | 68.71 |
Starbucks stands out as the world's biggest and most recognizable coffee brand, powered by ultracustomizable beverages in-store and a sweeping footprint of nearly 41,000 cafes in over 80 countries. About 52% are company-operated, with the balance run by licensees. The company operates roasteries and sells across its North America (74% of revenue as of the end of fiscal 2025), international (21%), and channel development (5%) segments. The brand collects revenue from company-operated stores, licensee royalties, equipment and product sales, retail ready-to-drink beverages, and packaged coffee.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.